Copyright: It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Quality of Life: A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.DNA Barcoding, Taxonomic: Techniques for standardizing and expediting taxonomic identification or classification of organisms that are based on deciphering the sequence of one or a few regions of DNA known as the "DNA barcode".Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Physical Examination: Systematic and thorough inspection of the patient for physical signs of disease or abnormality.Maximum Tolerated Dose: The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Infusions, Intravenous: The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.ConnecticutCancer Care Facilities: Institutions specializing in the care of cancer patients.Certification: Compliance with a set of standards defined by non-governmental organizations. Certification is applied for by individuals on a voluntary basis and represents a professional status when achieved, e.g., certification for a medical specialty.Schools: Educational institutions.Cellular Phone: Analog or digital communications device in which the user has a wireless connection from a telephone to a nearby transmitter. It is termed cellular because the service area is divided into multiple "cells." As the user moves from one cell area to another, the call is transferred to the local transmitter.GermanyBreast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Cubital Tunnel Syndrome: Compression of the ULNAR NERVE in the cubital tunnel, which is formed by the two heads of the flexor carpi ulnaris muscle, humeral-ulnar aponeurosis, and medial ligaments of the elbow. This condition may follow trauma or occur in association with processes which produce nerve enlargement or narrowing of the canal. Manifestations include elbow pain and PARESTHESIA radiating distally, weakness of ulnar innervated intrinsic hand muscles, and loss of sensation over the hypothenar region, fifth finger, and ulnar aspect of the ring finger. (Joynt, Clinical Neurology, 1995, Ch51, p43)Tarsal Tunnel Syndrome: Entrapment of the distal branches of the posterior TIBIAL NERVE (which divides into the medial plantar, lateral plantar, and calcanial nerves) in the tarsal tunnel, which lies posterior to the internal malleolus and beneath the retinaculum of the flexor muscles of the foot. Symptoms include ankle pain radiating into the foot which tends to be aggravated by walking. Examination may reveal Tinel's sign (radiating pain following nerve percussion) over the tibial nerve at the ankle, weakness and atrophy of the small foot muscles, or loss of sensation in the foot. (From Foot Ankle 1990;11(1):47-52)Brachial Plexus Neuritis: A syndrome associated with inflammation of the BRACHIAL PLEXUS. Clinical features include severe pain in the shoulder region which may be accompanied by MUSCLE WEAKNESS and loss of sensation in the upper extremity. This condition may be associated with VIRUS DISEASES; IMMUNIZATION; SURGERY; heroin use (see HEROIN DEPENDENCE); and other conditions. The term brachial neuralgia generally refers to pain associated with brachial plexus injury. (From Adams et al., Principles of Neurology, 6th ed, pp1355-6)Ulnar Nerve Compression Syndromes: Ulnar neuropathies caused by mechanical compression of the nerve at any location from its origin at the BRACHIAL PLEXUS to its terminations in the hand. Common sites of compression include the retroepicondylar groove, cubital tunnel at the elbow (CUBITAL TUNNEL SYNDROME), and Guyon's canal at the wrist. Clinical features depend on the site of injury, but may include weakness or paralysis of wrist flexion, finger flexion, and ulnar innervated intrinsic hand muscles, and impaired sensation over the ulnar aspect of the hand, fifth finger, and ulnar half of the ring finger. (Joynt, Clinical Neurology, 1995, Ch51, p43)Musculoskeletal Abnormalities: Congenital structural abnormalities and deformities of the musculoskeletal system.Complex Regional Pain Syndromes: Conditions characterized by pain involving an extremity or other body region, HYPERESTHESIA, and localized autonomic dysfunction following injury to soft tissue or nerve. The pain is usually associated with ERYTHEMA; SKIN TEMPERATURE changes, abnormal sudomotor activity (i.e., changes in sweating due to altered sympathetic innervation) or edema. The degree of pain and other manifestations is out of proportion to that expected from the inciting event. Two subtypes of this condition have been described: type I; (REFLEX SYMPATHETIC DYSTROPHY) and type II; (CAUSALGIA). (From Pain 1995 Oct;63(1):127-33)Amputation Stumps: The part of a limb or tail following amputation that is proximal to the amputated section.Survivors: Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.Metabolic Syndrome X: A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)Syndrome: A characteristic symptom complex.Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Neoplasms, Second Primary: Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.Nerve Sheath Neoplasms: Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.Peripheral Nervous System Neoplasms: Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)Neurofibromatosis 1: An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).Neurofibroma: A moderately firm, benign, encapsulated tumor resulting from proliferation of SCHWANN CELLS and FIBROBLASTS that includes portions of nerve fibers. The tumors usually develop along peripheral or cranial nerves and are a central feature of NEUROFIBROMATOSIS 1, where they may occur intracranially or involve spinal roots. Pathologic features include fusiform enlargement of the involved nerve. Microscopic examination reveals a disorganized and loose cellular pattern with elongated nuclei intermixed with fibrous strands. (From Adams et al., Principles of Neurology, 6th ed, p1016)Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.Sarcoma, Synovial: A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)Airports: Terminal facilities used for aircraft takeoff and landing and including facilities for handling passengers. (from McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed.)Martial Arts: Activities in which participants learn self-defense mainly through the use of hand-to-hand combat. Judo involves throwing an opponent to the ground while karate (which includes kung fu and tae kwon do) involves kicking and punching an opponent.History of NursingKinesin: A microtubule-associated mechanical adenosine triphosphatase, that uses the energy of ATP hydrolysis to move organelles along microtubules toward the plus end of the microtubule. The protein is found in squid axoplasm, optic lobes, and in bovine brain. Bovine kinesin is a heterotetramer composed of two heavy (120 kDa) and two light (62 kDa) chains. EC 3.6.1.-.Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277)Wine: Fermented juice of fresh grapes or of other fruit or plant products used as a beverage.Intracranial Hypotension: Reduction of CEREBROSPINAL FLUID pressure characterized clinically by HEADACHE which is maximal in an upright posture and occasionally by an abducens nerve palsy (see ABDUCENS NERVE DISEASES), neck stiffness, hearing loss (see DEAFNESS); NAUSEA; and other symptoms. This condition may be spontaneous or secondary to SPINAL PUNCTURE; NEUROSURGICAL PROCEDURES; DEHYDRATION; UREMIA; trauma (see also CRANIOCEREBRAL TRAUMA); and other processes. Chronic hypotension may be associated with subdural hematomas (see HEMATOMA, SUBDURAL) or hygromas. (From Semin Neurol 1996 Mar;16(1):5-10; Adams et al., Principles of Neurology, 6th ed, pp637-8)Neurosurgery: A surgical specialty concerned with the treatment of diseases and disorders of the brain, spinal cord, and peripheral and sympathetic nervous system.Health Maintenance Organizations: Organized systems for providing comprehensive prepaid health care that have five basic attributes: (1) provide care in a defined geographic area; (2) provide or ensure delivery of an agreed-upon set of basic and supplemental health maintenance and treatment services; (3) provide care to a voluntarily enrolled group of persons; (4) require their enrollees to use the services of designated providers; and (5) receive reimbursement through a predetermined, fixed, periodic prepayment made by the enrollee without regard to the degree of services provided. (From Facts on File Dictionary of Health Care Management, 1988)Neurosurgical Procedures: Surgery performed on the nervous system or its parts.Dermatoglyphics: The study of the patterns of ridges of the skin of the fingers, palms, toes, and soles.DNA Fingerprinting: A technique for identifying individuals of a species that is based on the uniqueness of their DNA sequence. Uniqueness is determined by identifying which combination of allelic variations occur in the individual at a statistically relevant number of different loci. In forensic studies, RESTRICTION FRAGMENT LENGTH POLYMORPHISM of multiple, highly polymorphic VNTR LOCI or MICROSATELLITE REPEAT loci are analyzed. The number of loci used for the profile depends on the ALLELE FREQUENCY in the population.Research: Critical and exhaustive investigation or experimentation, having for its aim the discovery of new facts and their correct interpretation, the revision of accepted conclusions, theories, or laws in the light of newly discovered facts, or the practical application of such new or revised conclusions, theories, or laws. (Webster, 3d ed)Craniotomy: Any operation on the cranium or incision into the cranium. (Dorland, 28th ed)

Study on chemoprevention of hepatocellular carcinoma by ginseng: an introduction to the protocol. (1/58)

In patients with chronic hepatitis C virus disease, there is a high incidence of development of hepatocellular carcinoma (HCC) in the process of transition from chronic hepatitis to hepatic cirrhosis. Although ginseng traditionally has been used mainly as a nutritional supplement in Asian countries, a case-control study found that it may inhibit the development of HCC. We therefore planned a clinical study of HCC prevention by medicinal ginseng. The subjects are patients with chronic C virus disease (chronic hepatitis and hepatic cirrhosis), who are high risk group for HCC. This intervention study is a multi-center, double-blind, randomized controlled trial. The participants will be randomly divided into two groups. The test sample (1 g of red ginseng powder per day) will be administered for 5 yr, and ginseng intake will be prohibited during the administration period. The primary endpoint of this study is the development of HCC. Target number of recruiting subjects are 300. The participants should be registered from February 2001 to January 2003.  (+info)

Guidelines for the treatment of recurrent and metastatic cervical cancer. (2/58)

Although there have been important advances in the management of women with cervical cancer, the optimal treatment for patients with locally recurrent and metastatic disease is still problematic, and there are relatively few randomized trials to guide treatment decisions. This paper reviews the approach to management of patients who relapse after primary treatment for cervical cancer. Patients who are still potentially curable with radical treatment are identified, and the various treatment strategies are discussed. However, most women are treated with palliative intent, and the literature on palliative management is reviewed together with the levels of evidence.  (+info)

High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. (3/58)

OBJECTIVE: To identify patient characteristics associated with the development of local recurrence and the effect of local recurrence on subsequent morbidity and mortality in patients with intermediate- to high-grade extremity soft tissue sarcomas. SUMMARY BACKGROUND DATA: Numerous studies on extremity soft tissue sarcomas have consistently shown that presentation with locally recurrent disease is associated with the development of subsequent local recurrences and that large tumor size and high histologic grade are significant factors associated with decreased survival. However, the effect of local recurrence on patient survival remains unclear. METHODS: From 1975 to 1997, 753 patients with intermediate- to high-grade extremity soft tissue sarcomas were treated at UCLA. Treatment outcomes and patient characteristics were analyzed to identify factors associated with both local recurrence and survival. RESULTS: Patients with locally recurrent disease were at a significantly increased risk of developing a subsequent local recurrence. Local recurrence was a morbid event requiring amputation in 38% of the cases. The development of a local recurrence was the most significant factor associated with decreased survival. Once a patient developed a local recurrence, he or she was about three times more likely to die of disease compared to similar patients who had not developed a local recurrence. CONCLUSIONS: Local recurrence in patients with intermediate- to high-grade extremity soft tissue sarcomas is associated with the development of subsequent local recurrences, a morbid event decreasing functional outcomes and the most significant factor associated with decreased survival. Although 85% to 90% of patients with high-grade extremity soft tissue sarcomas are treatable with a limb salvage approach, patients who develop a local recurrence need aggressive treatment and should be considered for trials of adjuvant systemic therapy.  (+info)

Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. (4/58)

BACKGROUND: In primary central high-grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy. METHODS: The authors investigated whether the subtypes correlated with histologic response to chemotherapy in 1058 patients with osteosarcoma of the extremities who were treated with neoadjuvant chemotherapy over the last 20 years. The tumors were classified as osteoblastic (70%), chondroblastic (13%), fibroblastic (9%), and telangiectatic (6%). At diagnosis, 911 patients had localized disease and 147 had resectable lung metastases. RESULTS: The response to preoperative chemotherapy was good (90% or more tumor necrosis) in 59% of patients and poor (< 90% tumor necrosis) in 41% of patients. The rate of good responses was significantly higher (P = 0.0001) in the fibroblastic (83%) and telangiectatic (80%) tumors and significantly lower in chondroblastic tumors (43%). Prognosis was significantly correlated with the histologic subtypes. The 5-year overall survival rate was significantly higher (P = 0.0001) in fibroblastic (83%) and telangiectatic (75%) tumors than in osteoblastic (62%) and chondroblastic (60%) tumors. In all subtypes, except for the chondroblastic subtype, the 5-year overall survival rate was significantly higher (P = 0.0001) in good responders P = 0.0001 (68%) than in poor responders (52%). CONCLUSIONS: The authors concluded that the histologic subtype of primary central high-grade osteosarcoma of the extremity was strictly correlated with histologic response to chemotherapy and probably, as a consequence, also with prognosis. Further studies are needed to establish whether these results justify a specific therapeutic approach based on the histologic subtype of the tumor.  (+info)

The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. (5/58)

To examine the influence of the pathology review mechanism on the results of analyses of therapeutic efficacy and biological prognostic correlates for pediatric high-grade gliomas, we evaluated the effects of using single-expert review or consensus review, as alternatives to institutional classification, in determining outcome results of a large randomized trial. The study group was the randomized cohort of Children's Cancer Group study 945, which compared efficacy of 2 chemotherapy regimens adjuvant to surgery and radiation. Trial eligibility required institutional histopathologic diagnosis of high-grade glioma. Sections of study tumors also were centrally reviewed, initially by a study review neuropathologist and subsequently by 5 neuropathologists, including the review pathologist. Reviews were independent, and reviewers were masked to clinical factors and outcomes, and consensus diagnoses of the panel were then established. Among 172 eligible patients, 42 tumors were classified as discordant on single-expert review and 51 on consensus review. Progression-free survival probabilities calculated for patients with tumors classified as high-grade gliomas by either single-expert or consensus review were inferior to those for the overall, institutionally diagnosed cohort. However, conclusions of the study regarding relative efficacy of treatment and clinical and molecular outcome correlates were unaffected by diagnosis method. Resection extent, proliferation index, and p53 expression were associated strongly with outcome, regardless of diagnosis method. However, comparisons between arms in which inclusion was determined by different review criteria for each arm caused spurious conclusions about efficacy differences between treatments. We conclude that the pathology review mechanism had little effect on within-trial comparisons of therapeutic effects or prognostic correlates in this randomized study, but strongly influenced survival distributions that were calculated for each treatment arm. These results support the implementation of expedited central review in therapeutic studies involving childhood malignant gliomas as a way to prospectively identify and exclude cases with discordant diagnoses and indicate the need for additional measures, such as molecular assessments, to increase the reproducibility of neuropathologic classification for these tumors.  (+info)

Implementing clinical protocols in oncology: quality gaps and the learning curve phenomenon. (6/58)

BACKGROUND: The quality improvement effort in clinical practice has focused mostly on 'performance quality', i.e. on the development of comprehensive, evidence-based guidelines. This study aimed to assess the 'conformance quality', i.e. the extent to which guidelines once developed are correctly and consistently applied. It also aimed to assess the existence of quality gaps in the treatment of certain patient segments as defined by age or gender and to investigate methods to improve overall conformance quality. METHODS: A retrospective audit of clinical practice in a well-defined oncology setting was undertaken and the results compared to those obtained from prospectively applying an internally developed clinical protocol in the same setting and using specific tools to increase conformance quality. RESULTS: All indicators showed improvement after the implementation of the protocol that in many cases reached statistical significance, while in the entire cohort advanced age was associated (although not significantly) with sub-optimal delivery of care. A 'learning curve' phenomenon in the implementation of quality initiatives was detected, with all indicators improving substantially in the second part of the prospective study. CONCLUSIONS: Clinicians should pay separate attention to the implementation of chosen protocols and employ specific tools to increase conformance quality in patient care.  (+info)

Probabilistic reporting of EUS-FNA cytology: Toward improved communication and better clinical decisions. (7/58)

BACKGROUND: The objectives of this study were to determine threshold probabilities needed to perform endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and those needed to treat patients suspected of having malignancy and then to compare these thresholds to the pre- and posttest probabilities of malignancy associated with benign, atypical, suspicious, and malignant diagnoses. The goal was to aid endoscopists in making appropriate clinical decisions based on both quantitative and qualitative approaches. METHODS: The study included 633 consecutive patients. A decision tree was constructed to estimate the "treatment" threshold. Using treatment threshold and likelihood ratios, the authors determined the "no-test-test" and "test-treatment" thresholds. Pretest probability was compared with no-test-test and test-treatment thresholds, and the post-EUS-FNA probability of malignancy for each diagnostic category with the treatment threshold. Results were stratified by lesion site, lesion size, and cytopathologist. RESULTS: EUS-FNA has a wide range of pretest probabilities within which it could be performed (0.06-0.98). The posttest probabilities for malignancy, 0.99 (95% confidence interval [CI], 0.967-0.996) and 0.09 (95% CI, 0.057-0.126), after a positive or a negative result, respectively, were significantly different from the treatment threshold but not those of suspicious, 0.92 (95% CI, 0.767-0.994) diagnosis. The posttest probability of atypical diagnosis, 0.60 (95% CI, 0.407-0.772), was not significantly different from that of pretest probability. Results did not vary by lesion size, organ site, or cytopathologist. CONCLUSION: The authors demonstrated the uncertainty associated with EUS-FNA diagnostic categories and used the threshold approach to qualify quantitatively the decision to perform EUS-FNA and the decision to treat patients suspected of having malignancy.  (+info)

Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. (8/58)

BACKGROUND: Adjuvant chemotherapy has been proven to be beneficial for patients with early stage non-small cell lung cancer. However, toxicity and insufficient dose delivery have been critical issues with the chemotherapy used. Doublet regimens with pemetrexed, a multi-target folate inhibitor, and platin show clear activity in non-small cell lung cancer and are well tolerated with low toxicity rates and excellent delivery. METHODS/DESIGN: In this prospective, multi-center, open label randomized phase II study, patients with pathologically confirmed non-small cell lung cancer, stage IB, IIA, IIB, T3N1 will be randomized after complete tumor resection either to 4 cycles of the standard adjuvant vinorelbine and cisplatin regimen from the published phase III data, or to 4 cycles of pemetrexed 500 mg/m2 d1 and cisplatin 75 mg/m2 d1, q 3 weeks. Primary objective is to compare the clinical feasibility of these cisplatin doublets defined as non-occurrence of grade 4 neutropenia and/or thrombocytopenia > 7 days or bleeding, grade 3/4 febrile neutropenia and/or infection, grade 3/4 non-hematological toxicity, non-acceptance leading to premature withdrawal and no cancer or therapy related death. Secondary parameters are efficacy (time to relapse, overall survival) and drug delivery. Parameters of safety are hematologic and non-hematologic toxicity of both arms. DISCUSSION: The TREAT trial was designed to evaluate the clinical feasibility, i.e. rate of patients without dose limiting toxicities or premature treatment withdrawal or death of the combination of cisplatin and pemetrexed as well as the published phase III regimen of cisplatin and vinorelbine. Hypothesis of the study is that reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and perhaps survival.  (+info)

*List of MeSH codes (N05)

... clinical protocols MeSH N05.715.360.775.225.500 --- antineoplastic protocols MeSH N05.715.360.775.235 --- clinical trials MeSH ...

*List of MeSH codes (E02)

... antineoplastic combined chemotherapy protocols MeSH E02.319.310.075 --- antiretroviral therapy, highly active MeSH E02.319. ... antineoplastic combined chemotherapy protocols MeSH E02.319.162.150 --- antibiotic prophylaxis MeSH E02.319.300.253 --- delayed ... antineoplastic combined chemotherapy protocols MeSH E02.190.044.080 --- acupressure MeSH E02.190.044.105 --- acupuncture ...

*FLAG (chemotherapy)

The FLAMSA protocol is most often used as an induction part of a reduced-intensity conditioning regimen for patients eligible ... G-CSF is still included, even though the "G" is taken out of the acronym.) Amsacrine is an alkylating antineoplastic agent that ... November 1994). "FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ' ... clinical protocols and preliminary results]". Deutsche Medizinische Wochenschrift (in German). 127 (42): 2186-92. doi:10.1055/s ...

*Closed system drug transfer device

This protocol is aimed as being a test standard for Closed Systems to assess 'closeness' of each system. ISOPP, the ... Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind.Med 1992;49:855-61 Sessink PJM, Kroese ... This protocol had an initial close date of November 2015 but was extended until March 2016. This period highlighted may ... In September 2015, the CDC issued a proposal for a testing protocol designed to test various CSTDs on the market today to help ...

*RTL6

Nature Protocols, 5: 725-738, 2010. Y Zhang. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 9: 40, ... "Genotoxicity of the copper antineoplastic coordination complexes casiopeinas". Toxicology in Vitro. 25 (7): 1376-84. doi: ...

*Duocarmycin

Bizelesin is antineoplastic antibiotic which binds to the minor groove of DNA and induces interstrand cross-linking of DNA, ... setting and agents that are less susceptible to these mechanisms can successfully be used in prolonged treatment protocols. ... represent a new class of highly potent antineoplastic compounds. The work of Dale L. Boger and others created a better ...

*Chemotherapy

Antineoplastic Agents in Encyclopedia of Molecular Pharmacology, 2nd Edition, Volume 1. Eds. Offermanns S and Rosenthal W. ... Generating Inhibitors of P-Glycoprotein: Where to, Now?. Springer Protocols. pp. 405-432. Luqmani YA (2005). "Mechanisms of ... Podophyllotoxin is an antineoplastic lignan obtained primarily from the American Mayapple (Podophyllum peltatum) and Himalayan ... The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs. ...

*Miltefosine

Previously one could only get it from the CDC for emergency use under an expanded access IND protocol for treatment of free- ... Initial in vivo investigation on the antineoplastic activity showed positive result, but then only at high dosage and at high ... demonstrated that the antineoplastic activity of the phospholipid analogue miltefosine (at the time known as ...

*Thymidine kinase

A standardized protocol that will help comparison of clinical studies has been suggested. Hybridomas are cells obtained by ... a biochemical strategy to enhance the activation of antineoplastic drugs". P R Health Sci J. 13 (1): 19-23. PMID 8016290. Sun R ... interferes with this regulatory mechanism and thereby increases the cytotoxicity of thymidine analogues used as antineoplastic ... "Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5 ...

*Asparaginase

"8.1.5: Other antineoplastic drugs". British National Formulary (BNF 57). United Kingdom: BMJ Group and RPS Publishing. March ... is also used in some mast cell tumor protocols. Unlike most of other chemotherapy agents, asparaginase can be given as an ...

*Iatrogenesis

Alkylating antineoplastic agents, for example, cause DNA damage, which is more harmful to cancer cells than regular cells. ... Antiseptics, anesthesia, antibiotics, better surgical techniques, evidence-based protocols and best practices continue to be ...

*Platinum

... -based antineoplastic agents are used in chemotherapy, and show good activity against some tumors. As platinum is a ... Carinder, James A.; Morrison, Pilar M.; Morrison, David G.; Jack E. Saux III (7 July 2014). Practical Oncology Protocols. Mill ...

*Azacitidine

It is thought to have antineoplastic activity via two mechanisms - at low doses, by inhibiting of DNA methyltransferase, ... 5-Aza-2'-Deoxycytidine information and protocols to study DNA methylation. ...

*Index of HIV/AIDS-related articles

... protocol - protozoa - provirus - pruritus - pseudo-Cushing's syndrome - pseudovirion - PUBMED - pulmonary - purified protein ... antineoplastic - antiprotozoal - antiretroviral drugs - antisense drugs - antitoxins - Antiviral drug - aphasia - aphthous ...

*Glutathione

The antineoplastic mustard drug canfosfamide was modelled on the structure of glutathione. Several studies have been completed ... Nature Protocols. 8 (9): 1660-9. doi:10.1038/nprot.2013.095. PMID 23928499. Farkas E, Buglyó P (2017). "Chapter 8. Lead(II) ...

*Drug discovery

For certain therapy areas, such as antimicrobials, antineoplastics, antihypertensive and anti-inflammatory drugs, the numbers ... agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis". Bioorganic & Medicinal Chemistry Letters ...

*Hepatocellular carcinoma

There remains controversy as to the most effective screening protocols. For example, while there is data to support decreased ... "Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells". Biochemical ... depending on the duration of diabetes and treatment protocol. A suspected contributor to this increased risk is circulating ...

*Streptomyces

Staurosporine (from S. staurosporeus) also has a range of activities from antifungal to antineoplastic (via the inhibition of ... Protocols / Resources S. avermitilis genome homepage (Kitasato Institute for Life Sciences) S. coelicolor A3(2) genome homepage ... are antineoplastic (anticancer) drugs; boromycin (from S. antibioticus) exhibits antiviral activity against the HIV-1 strain of ...
Background:Substantial progress has been made in the multimodality treatment of soft tissue sarcoma over the past decade. This review summarizes current state-of-the-art management for patients with...
Although multimodal management of extremity soft tissue sarcoma (STS) is the standard of care, considerable variation exists in the sequencing of radiotherapy (RT) or chemotherapy (CT). Our goal was t
Since publication of the first edition, Lower Extremity Soft Tissue & Cutaneous Plastic Surgery has attracted wide acclaim for its superb illustrations, clear step-by-step approach, thoroughness and practicality. Progressing from basic information on inst
Learn about Fareston (Toremifene) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
I say backlog because I started this about 5 weeks ago and figured after searching this and other forums for info I should provide my own. My history:
TY - JOUR. T1 - Adult Pilocytic Astrocytoma. T2 - An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. AU - Bond, Kamila M.. AU - Hughes, Joshua D.. AU - Porter, Amanda L.. AU - Orina, Josiah. AU - Fang, Shanna. AU - Parney, Ian F.. PY - 2018/2/1. Y1 - 2018/2/1. N2 - Introduction Pilocytic astrocytoma is a classically benign tumor that most often affects pediatric patients. Rarely, it occurs during adulthood. We present a case series and systematic literature review of adult pilocytic astrocytoma (APA) to examine the clinical presentation, extent of resection, and recurrence rate associated with this tumor in this population. Materials and Methods Our institutional records were retrospectively reviewed for cases of pilocytic astrocytoma in adults. A PubMed search identified English-language studies of pathology-proven APA. A meta-analysis was performed to determine the relationship between extent of tumor resection and recurrence. Results Forty-six ...
View details of top juvenile pilocytic astrocytoma hospitals in New Delhi. Get guidance from medical experts to select best juvenile pilocytic astrocytoma hospital in New Delhi
Find people with Juvenile Pilocytic Astrocytoma through the map. Connect with them and share experiences. Join the Juvenile Pilocytic Astrocytoma community.
Background The importance of functional outcome (FO) in the treatment of patients with extremity soft tissue sarcoma (STS) has been increasingly recognized in the last three decades. This systematic...
Only five spots left!. Join Laurie Hartman DO, PhD for a Special Short Notice One Day Lab Course Tuesday Sept 20th in Costa Mesa CA.. Laurie Hartman is Associate Professor of Osteopathic Technique at the British School of Osteopathy, and has been teaching osteopathic and manipulative technique and manual therapy since 1964. He is in great demand internationally and has taught and lectured in 17 different countries.. This Master Class Technique Course is limited to 10 Physical Therapists, with manual therapy experience.. Tuesday September 20th- 9am to 5pm. ...
Davis AM, OSullivan B, Bell RS, Turcotte R, Catton CN, Wunder JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B: Function and Health Status Outcomes in a Radomized Trial Comparing Preoperative and Postoperative Radiotherapy in Extremity Soft Tissue Sarcoma. Journal of Clinical Oncology 2002: 20: pp 4472-4477. ...
The IUPHAR/BPS Guide to Pharmacology. toremifene ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
The IUPHAR/BPS Guide to Pharmacology. toremifene ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
If someone has had chemotherapy treatments for the above mentioned (brain) tumor, does it mean he/she has cancer? I thought chemo is only to treat cancer cells, however Ive read an article that it,...
Basic Views Name:Toremifene Citrate Synonyms: FC 1157a; Fareston; NK 622; NSC 613680 CAS: 89778-27-8 Appearance: White or almost white powder Purity:98% Package: 5kg/barrel or as your inquiry Molecular Formula: C26H28ClNO·C6H8O7 Molecular Weight:...
Toremifine is an anti-oestrogen hormone that is used in the treatment of breat cancer. Read more about toremifine online at Patient
China Toremifene Citrate/CAS: 89778-27-8 Raw Powder, Find details about China Toremifene Citrate, 89778-27-8 from Toremifene Citrate/CAS: 89778-27-8 Raw Powder - Zhuhai Jiaxinkang Pharmaceutical & Chemical Co., Ltd.
Toremifene citrate increases the testosterone level over the period of administration. Most bodybuilders suffer from aromatization of steroids under an ...

GENERIC 3204009-Antineoplastic+Combined+Chemotherapy+ProtocolsGENERIC 3204009-Antineoplastic+Combined+Chemotherapy+Protocols

Protocols Source:http://linkedlifedata.com/resource/pubmed/meshheading/3204009-Antineoplastic+Combined+Chemotherapy+Protocols ...
more infohttp://linkedlifedata.com/resource/pubmed-meshheading/3204009-Antineoplastic%2BCombined%2BChemotherapy%2BProtocols

A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors. - Full Text View -...A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors. - Full Text View -...

Must meet protocol lab criteria which will include lab assessment of adequate bone marrow function, liver function, and renal ... History of uncontrolled heart disease within 12 months before enrollment or any protocol-defined cardiovascular abnormalities ...
more infohttps://clinicaltrials.gov/show/NCT00651365

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C) > Surgery | Yale School of...Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C) > Surgery | Yale School of...

Antineoplastic Protocols. *Breast Cyst. *Genes, Neoplasm. *Early Detection of Cancer. *Hereditary Breast and Ovarian Cancer ...
more infohttps://medicine.yale.edu/surgery/specialties/anees_chagpar-3.profile

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy RegimenSatraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Cancer Treatment Protocols. *Antineoplastic protocols. *One Prior Cytotoxic Chemotherapy Regimen. *Prostatic Neoplasms ...
more infohttp://www.knowcancer.com/cancer-trials/NCT00069745/

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine...Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine...

Antineoplastic Protocols. *Immunotherapy. *Metastatic breast cancer. *Advanced breast cancer. *Stage III to IV breast cancer ...
more infohttp://www.knowcancer.com/cancer-trials/NCT00452140/

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C) > Breast Center | Surgery | Oncology | Yale School of...Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C) > Breast Center | Surgery | Oncology | Yale School of...

Antineoplastic Protocols. *Breast Cyst. *Genes, Neoplasm. *Early Detection of Cancer. *Hereditary Breast and Ovarian Cancer ...
more infohttp://medicine.yale.edu/surgery/oncology/breastcenter/surgeons/anees_chagpar-3.profile

Program Members > Yale Cancer Center | Yale School of...Program Members > Yale Cancer Center | Yale School of...

Antineoplastic Protocols; Breast; Breast Cyst; Breast Diseases; Breast Neoplasms; Breast Neoplasms, Male; Breast Self- ...
more infohttp://yalecancercenter.org/patient/programs/breast/members/

Metabolic Syndrome Induced by Anticancer Treatment in Childhood Cancer Survivors - PubMedMetabolic Syndrome Induced by Anticancer Treatment in Childhood Cancer Survivors - PubMed

Keywords: Antineoplastic protocols; Life style; Metabolic syndrome X; Neoplasms; Survivors. Conflict of interest statement ...
more infohttps://pubmed.ncbi.nlm.nih.gov/28690985/

IGF Type 1 Receptor
      - IGF 1 Receptor
     Summary Report | CureHunterIGF Type 1 Receptor - IGF 1 Receptor Summary Report | CureHunter

Antineoplastic Protocols CureHunter Inc. provides medical information and specifically does NOT provide medical advice. ...
more infohttp://www.curehunter.com/public/keywordSummaryD017526-IGF-Type-1-Receptor-IGF-1-Receptor.do

figo stage iib cervix uteri carcinoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginefigo stage iib cervix uteri carcinoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Uterine ... MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Laparoscopy. ... MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Apoptosis / physiology ... MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / therapy ...
more infohttp://www.bmlsearch.com/?kwr=figo+stage+iib+cervix+uteri+carcinoma+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

askins tumor morphologic abnormality 2005:2010[pubdate] *count=100 - BioMedLib™ search engineaskin's tumor morphologic abnormality 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroectodermal Tumors, Primitive / drug therapy ... MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Neuroectodermal ... Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy / adverse effects. Combined ... Antineoplastic Protocols. Combined Modality Therapy. Humans. Pediatrics. Prognosis. Protein Kinases / physiology. Receptor, IGF ...
more infohttp://www.bmlsearch.com/?kwr=askin

A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a...A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a...

A study protocol for the evaluation of occupational mutagenic/carcinogenic risks in subjects exposed to antineoplastic drugs: a ... Occupational genotoxic risks in healthcare workers handling antineoplastic drugs: scheme of the study protocol. CP: ... A modified protocol that uses a DNA repair inhibitor has been proposed as a means for increasing the sensitivity of the assay [ ... A multiplex PCR method will be used to detect the presence or absence of the GSTM1 and GSTT1 genes, according to the protocol ...
more infohttps://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-195

Medical Social Sciences - Research Output
     - Northwestern ScholarsMedical Social Sciences - Research Output - Northwestern Scholars

Enhancing behavioral treatment for women with pelvic floor disorders: Study protocol for a pilot randomized controlled trial. ... Protocol for a randomized controlled trial. Yanez, B., Baik, S. H., Oswald, L. B., Buitrago, D., Buscemi, J., Iacobelli, F., ...
more infohttps://www.scholars.northwestern.edu/en/organisations/medical-social-sciences/publications/?type=%2Fdk%2Fatira%2Fpure%2Fresearchoutput%2Fresearchoutputtypes%2Fcontributiontojournal%2Farticle

Habermann, T. M.<...Habermann, T. M.<...

Hill, B. T., Nastoupil, L., Winter, A. M., Becnel, M. R., Cerhan, J. R., Habermann, T. M., Link, B. K., Maurer, M. J., Fakhri, B., Reddy, P., Smith, S. D., Mukhija, D., Jagadeesh, D., Desai, A., Alderuccio, J. P., Lossos, I. S., Mehra, P., Portell, C. A., Goldman, M. L., Calzada, O. & 9 othersCohen, J. B., Hussain, M. J., Ghosh, N., Caimi, P., Tiutan, T., Martin, P., Kodali, A., Evens, A. M. & Kahl, B. S., Feb 1 2019, In : British Journal of Haematology. 184, 4, p. 524-535 12 p.. Research output: Contribution to journal › Article ...
more infohttps://mayoclinic.pure.elsevier.com/en/persons/thomas-matthew-habermann

Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation,...Effect of Metformin and Sitagliptin on Doxorubicin-Induced Cardiotoxicity in Rats: Impact of Oxidative Stress, Inflammation,...

However, they are widely used in antineoplastic protocols because remission rates with these agents are superior to those of ... Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study ... Doxorubicin (DOX) is a common antineoplastic anthracycline antibiotic and is used for treatment of many types of cancer [1]. ... All animal care and experimental procedures were in accordance with the protocols of the Research Advisory Ethical Committee of ...
more infohttps://www.hindawi.com/journals/jt/2015/424813/

Neurosurgery - Fingerprint
     - Atlantic Health SystemNeurosurgery - Fingerprint - Atlantic Health System

Antineoplastic Combined Chemotherapy Protocols Enzymes Appointments and Schedules Central Nervous System Nervous System ...
more infohttps://ahs.pure.elsevier.com/en/organisations/neurosurgery/fingerprints/

Search of: nabilone OR cesamet AND Antiemetics - List Results - ClinicalTrials.govSearch of: nabilone OR cesamet AND Antiemetics - List Results - ClinicalTrials.gov

Antineoplastic Combined Chemotherapy Protocols. *Drug: Cesamet™ (nabilone). Interventional. Phase 4. *NEMA Research, Inc. ...
more infohttps://clinicaltrials.gov/ct2/results?term=nabilone+OR+cesamet+AND+Antiemetics

Feasibility and Safety of FLOT Regimen in Chinese Gastric Cancer PatientsFeasibility and Safety of FLOT Regimen in Chinese Gastric Cancer Patients

Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).. More From ... Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. ...
more infohttps://www.bioportfolio.com/resources/trial/216210/Feasibility-and-Safety-of-FLOT-Regimen-in-Chinese-Gastric-Cancer-Patients.html
  • The impressive 48% response rate reported for the combination of gemcitabine with cisplatin in a single phase II study has made this regimen the new standard of care for off-protocol treatment of this disease, although this trial still requires validation. (biomedsearch.com)